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Abstract. Follicular adenoma is a type of benign and
encapsulated nodule in the thyroid gland, but some
adenomas have the potential to progress to follicular
carcinoma. Therefore, it is important to monitor the state and
progress of follicular adenoma in the clinic and discover
drug development targets for the treatment of follicular
adenoma to prevent its worsening to follicular carcinoma.
Currently, the study of biomarkers and therapeutic targets
lacks applications of up-to-date technologies, including
proteomics and bioinformatics. To discover novel protein
biomarker and therapeutic target candidates, a liquid
chromatography-tandem mass spectrometry approach was
applied to directly compare follicular adenoma with normal
thyroid tissue samples. The proteomics analysis revealed 114
protein biomarker candidates out of 1,780 identified and
quantified proteins. A comprehensive approach to prioritize
the biomarker candidates by category and rank revealed
CD63, DDB1, TYMP, VDAC2, and DCXR as the top five
biomarker candidates. Upstream regulator analysis using the
Ingenuity Pathway Analysis (IPA) software discovered four
therapeutic target candidates for follicular adenoma,
including TGFB1, MYC, ANGPT2, and NFE2L2. This study
provided biomarker and therapeutic target candidates for a
follow-up study, which will facilitate monitoring and
treatment of follicular adenoma.
A lump within the thyroid gland is called a thyroid nodule
and consists of an abnormal growth of thyroid cells. Most
are asymptomatic. Occasionally, a lump in the neck is
noticed by the patient. More often, a lump is discovered
incidentally during a medical procedure for completely
unrelated reasons. However, thyroid nodules are among the
most common endocrine complaints in the United States.
Approximately 10-20 million Americans have clinically-
detectable thyroid nodules (1) and nearly 50% of the
population have thyroid nodules at autopsy (2). 
According to the American Thyroid Association guidelines
on thyroid nodules and differentiated thyroid cancer published
2009, a series of medical history investigation, physical
examination, laboratory tests including measurement of
thyroid-stimulating hormone, ultrasonography, and fine
needle biopsy should be performed with the discovery of a
thyroid nodule (3). Fortunately, over 90% of thyroid nodules
are benign (1). 
Generally, benign nodules are not cancerous and do not
need to be removed, but should be watched closely with
ultrasound examination every 6-12 months and annual
physical examination (3, 4). However, among various types
of benign nodules, follicular adenoma has an increased risk
of malignancy, leading to follicular carcinoma (5, 6).
Therefore, it is extremely important to monitor the state and
development of follicular adenoma in clinical management
and find drug targets for the treatment of follicular adenoma
to prevent its worsening to follicular carcinoma.
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Currently, fine-needle aspiration (FNA) biopsy is the most
widely used and most accepted diagnostic test for a thyroid
nodule. However, several issues have been raised, including
the inherent inadequacy of cytological specimens in assessing
capsular and vascular involvement of thyroid follicular lesions
(7). Because the malignant nature of follicular lesions
requires histologic proof of capsular or vascular invasion, any
FNA diagnosis of a follicular lesion is inherently uncertain
(8). Alternatively, the analysis of BRAF, RAS, and other
mutations in cytological samples has been applied to
follicular adenoma management (8, 9). However, no marker
or group of markers has yet been sufficiently validated, and
measurements of molecular markers remain investigational
(7). The lack of convenient biomarkers, such as proteins in
plasma, makes monitoring of follicular adenomas difficult.
Thus, the current study aimed to profile the proteomic
differences between follicular adenoma and normal tissue in
order to explore the possible mechanisms and identify
potential biomarkers for the development of novel monitoring
techniques and therapeutic approaches.
Through literature search, we found approximately 10
articles reporting on proteomic profiling of follicular adenoma
(10-12). Among these, five have directly compared follicular
adenoma with normal tissue (13-17). However, only an
outdated proteomic technique, two-dimensional electrophoresis
technique, has been applied. Proteomic technology has
dramatically improved over the last decade. A shotgun
proteomics approach provides better profiling of proteins
because of its sensitivity and high-throughput capability (18).
Therefore, a liquid chromatography-tandem mass spectrometry
(LC-MS/MS) approach should be investigated on the
proteomic profiling of follicular adenoma. 
In the present study, fresh-frozen tissue samples of normal
and follicular adenoma were analyzed using a quantitative
LC-MS/MS approach. Profiling of the two groups of tissues
was carried-out for direct comparison. The results revealed
possible mechanisms and potential biomarkers involved in
follicular adenoma, significantly expanding the number of
meaningful biomarker candidates for monitoring follicular
adenoma and developing drugs to treat follicular adenoma
before it worsens to follicular carcinoma.
Materials and Methods
Materials. Urea, DL-dithiothreitol, triethylphosphine, iodoethanol,
and ammonium bicarbonate (NH4HCO3) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). LC-MS grade water (H2O),
LC-MS grade 0.1% formic acid in acetonitrile (ACN), and 0.1%
formic acid in water (H2O) were obtained from Burdick & Jackson
(Muskegon, MI, USA). Modified sequencing grade porcine trypsin
was purchased from Princeton Separations (Freehold, NJ, USA). 
Protein extraction. The study was approved by the Indiana University
Institutional Review Board (IRB #1206008865). Follicular adenoma
and normal tissues were obtained from the Indiana University Health
Methodist Research Institute (Indianapolis, IN, USA). Protein
extraction from the tissue samples was performed according to a
published procedure (19). After each tissue sample was weighed, it
was placed in a 50-ml beaker, and 8 volumes of lysis buffer were
added. The tissue was thoroughly minced with needle-nose surgical
scissors. The buffer/minced tissue solution was transferred to a ground-
glass homogenizer tube. The material was grinded-up by twisting with
an up/down motion until no solid tissue remained. The homogenates
were transferred into a 2-ml microcentrifuge tube and centrifuged at
15,000 × g for 10 min at -4 ˚C to remove insoluble materials. Fully-
solubilized samples were then stored at -80 ˚C until analysis. Protein
concentration was determined by the Bradford Protein Assay using
Bio-Rad protein assay dye reagent concentrate (20). 
Protein reduction, alkylation, and digestion. Protein reduction,
alkylation, and digestion were carried-out using a method previously
published by the author (21). Briefly, a 100-μg aliquot of protein
sample was placed in a 2 ml tube and then adjusted to 200 μl of 4
M urea by adding water. Two hundred μL of the
reduction/alkylation cocktail consisted of triethylphosphine and
iodoethanol were added to each of the tubes. The sample was
incubated at 35˚C for 60 min, dried by SpeedVac, and reconstituted
with 100 μL of 100 mM NH4HCO3 at pH 8.0. A 150 μL aliquot of
a 20 μg/mL trypsin solution was added to the sample and incubated
at 35˚C for 3 h, after which another 150 μL of trypsin was added,
and the solution incubated at 35˚C for 3 h.
LC-MS/MS analysis. The digested samples were analyzed using a
Thermo Scientific linear ion-trap (LTQ) mass spectrometer coupled
with a Surveyor autosampler and MS HPLC system (Thermo
Scientific, Waltham, MA, USA). Tryptic peptides were injected onto
the C18 RP column (TSKgel ODS-100V, 1.0 mm x 150 mm) at a
flow rate of 50 μl/min. The mobile phases A and B were 0.1%
formic acid in water and 50% ACN with 0.1% formic acid in water,
respectively. The gradient elution profile was as follows: 10.0% B
(90.0% A) for 7 min, 10.0-20.6% B (90.0-79.4% A) for 5 min, 20.6-
65.6% B (79.4-34.4% A) for 148 min, 65.6-100.0% B (34.4-0.0%
A) for 10 min, 100.0% B for 10 min. The data were collected in the
“Data-dependent MS/MS” mode with the ESI interface using
normalized collision energy of 35%. Dynamic exclusion settings
were set to repeat count 1, repeat duration 30 s, exclusion duration
120 s, and exclusion mass width 0.6 m/z (low) and 1.6 m/z (high).
Protein identification and quantification. Acquired data were
searched against the UniProt protein sequence database of HUMAN
(released on 10/03/2012) using SEQUEST (v.28 rev.12) algorithms
in Bioworks (v.3.3). General parameters were set to:  mass type set
as “monoisotopic precursor and fragments”, enzyme set as “trypsin
(KR)”, enzyme limits set as “fully enzymatic - cleaves at both
ends”, missed cleavage sites set at 2, peptide tolerance 2.0 amu,
fragment ion tolerance 1.0 amu, fixed modification set as +44 Da
on Cysteine, and no variable modifications used. The searched
peptides and proteins were validated by PeptideProphet (22) and
ProteinProphet (23) in the Trans-Proteomic Pipeline (TPP, v.3.3.0)
(http://tools.proteomecenter.org/software.php). Only proteins and
peptides with protein probability ≥0.9000 and peptide probability
≥0.8000 were reported. Protein quantification was performed using
a label-free quantification software package, IdentiQuantXL™
(Indianapolis, IN, USA) (24).
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Results and Discussion
Protein identification and quantification. From the normal
and follicular adenoma tissue samples, 1,812 protein groups
(unique proteins) with a probability ≥0.9 were identified by
6,853 peptides with a probability ≥0.8. In the identification
process, proteins identified with completely identical
peptides are placed into a single protein group. Among the
1,812 proteins, 1,114 proteins were identified with at least
two distinct peptides. To obtain more accurate
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Table I. The ranking of biomarker candidates in the Category 1. 
Rank ID Gene PFN PFF FD FC NP SS SD NC PIBAP
1 F8W022 CD63 0.2 0.2 0.0 5.2 2 7 3 6 70.0
2 F5GY55 DDB1 0.2 0.2 0.0 3.8 2 1 3 14 58.0
3 H9KVA0 TYMP 0.3 0.2 –0.2 3.3 2 10 9 5 51.9
4 P45880-1 VDAC2 0.3 0.7 0.3 2.5 2 4 3 5 50.7
5 Q7Z4W1 DCXR 0.2 0.2 0.0 4.3 2 4 0 1 50.0
6 B4DLZ5 NAGK 0.2 0.0 –0.2 4.0 3 4 0 9 47.7
7 P31040 SDHA 0.3 0.7 0.3 1.7 5 4 9 2 46.0
8 H0Y9B6 HEXB 0.0 0.3 0.3 2.3 2 4 0 5 45.0
9 P00739 HPR 0.3 0.8 0.5 1.6 2 10 3 1 45.0
10 H7C2Y0 SEPT2 0.2 0.2 0.0 3.0 2 4 0 6 42.0
11 Q9BXN1 ASPN 0.3 0.5 0.2 1.6 7 10 3 1 41.3
12 P34932 HSPA4 0.3 0.0 –0.3 3.0 4 4 3 12 39.7
13 G3XA98 FBLN5 0.5 0.7 0.2 1.5 3 10 3 3 38.2
14 P54652 HSPA2 0.2 0.3 0.2 1.5 3 4 9 3 38.2
15 F8VPE8 RPLP0 0.2 0.2 0.0 2.6 2 4 3 3 38.0
16 F5GWA7 PHB2 0.2 0.3 0.2 1.5 2 4 3 8 36.2
17 B4DY47 PHB 0.5 0.5 0.0 1.5 2 1 9 9 36.0
18 E7EN95 FLNB 0.5 0.3 –0.2 2.6 2 4 3 6 35.0
19 H0YIZ1 NPC2 0.3 0.3 0.0 1.9 2 10 0 4 35.0
20 P00915 CA1 0.7 0.5 –0.2 1.9 11 4 3 1 33.2
21 P84243 H3F3A 0.7 0.8 0.2 1.5 5 1 3 3 31.2
22 E9PRY8 EEF1D 0.3 0.3 0.0 1.8 3 4 3 3 31.0
23 B1AR63 HK1 0.0 0.2 0.2 1.5 2 4 3 2 30.2
24 B7Z4L4 RPN1 0.3 0.5 0.2 1.5 4 4 0 3 30.2
25 B4DZM8 PSMD5 0.2 0.0 –0.2 2.9 2 0 3 2 29.5
26 P14923 JUP 0.3 0.0 –0.3 2.1 2 7 3 6 28.7
27 F5GWX2 HEBP1 0.2 0.3 0.2 1.6 2 4 0 2 28.3
28 Q99832-3 CCT7 0.5 0.3 –0.2 2.0 2 4 3 3 27.0
29 O00232 PSMD12 0.3 0.2 –0.2 1.9 2 4 3 3 26.2
30 Q99714-2 HSD17B10 0.3 0.0 –0.3 1.5 4 4 9 2 25.7
31 E7EX44 CALD1 0.8 0.5 –0.3 2.0 4 4 3 4 25.0
32 Q9H3G5 CPVL 0.2 0.2 0.0 1.5 3 4 0 2 24.0
33 Q96C19 EFHD2 0.2 0.0 –0.2 2.7 2 0 0 1 23.8
34 P50502 ST13 0.5 0.3 –0.2 1.8 2 4 0 4 23.3
35 H0YL72 IDH3A 0.3 0.2 –0.2 1.5 3 4 3 1 21.9
36 O94874 UFL1 0.2 0.0 –0.2 1.7 3 4 0 1 20.5
37 E7ERW2 GOT2 0.5 0.3 –0.2 1.6 2 4 0 2 19.7
38 Q9UBV8 PEF1 0.3 0.0 –0.3 2.4 2 4 0 1 19.7
39 B2RDM2 TXNDC5 0.3 0.0 –0.3 1.5 2 4 3 4 19.7
40 P00492 HPRT1 0.2 0.0 –0.2 1.5 2 4 0 1 17.8
41 B4DXP9 ACTR1A 0.3 0.0 –0.3 1.7 2 4 0 3 17.0
42 E7EW08 SHMT1 0.3 0.0 –0.3 1.7 2 4 0 3 17.0
43 O43684-2 BUB3 0.2 0.0 –0.2 1.5 2 1 0 3 16.8
44 P38919 EIF4A3 0.2 0.0 –0.2 1.7 2 1 0 1 16.5
45 B3KST5 COPS4 0.5 0.0 –0.5 1.8 2 4 3 3 16.0
46 Q9Y678 COPG1 0.5 0.0 –0.5 1.7 5 4 0 2 14.5
47 H7BZT7 ESD 0.3 0.0 –0.3 1.5 2 4 0 1 13.7
PFN, Protein identification frequency in normal tissues; PFF, protein identification frequency in follicular adenoma tissues; FD, protein identification
frequency difference between normal and follicular adenoma tissues. FC, Fold change; NP, number of peptides; SS, score of subcellular location;
SD, score of involvement in targeted diseases and disorders; NC, network connectivity; and PIBAP, prioritization index of biomarker candidates for
assay of plasma/serum specimens. The PIBAP is calculated using a formula of FD × 10 + FC × 10 + FD × FC × 10 + NP + SS + SD + NC. 
quantification, multiple filters were applied to eliminate
unqualified peptides for protein quantification (24). The
complete list of quantified proteins is available in Table I
(to be provided upon request from the authors), including
1,780 protein groups quantified by 6,421 peptides. Among
them, 1,089 proteins were quantified with at least two
distinct peptides.
Biomarker candidates. Once numerous proteins are identified
and quantified in the biomarker discovery phase, the
challenging task is to determine which proteins should be
chosen for further validation using alternative approaches. A
comprehensive approach to prioritizing and ranking proteins
has been published by the authors (25). One of the aims of
the present study was to discover biomarker candidates to
monitor follicular adenoma in clinical management by
testing the blood level of certain proteins. An ideal biomarker
should be low abundance in normal tissue while high
abundance in follicular adenoma tissue. Volcano plots in
Figure 1 illustrate the protein changes between normal and
follicular tissues. Only proteins highlighted in the red square
are up-regulated by at least 1.5-fold and considered potential
biomarker candidates for further prioritization and rank.
Excluding protein isoforms, 114 unique proteins were
considered biomarker candidates.
Prioritizing the biomarker candidates by categorizing. To
have a better chance of success in biomarker validation, we
categorized the candidates with different priorities
according to the most critical factors. Because residual
blood could be present in the tissue samples, proteins from
blood rather than the tissue cells would be identified as
well. However, these proteins should not be easily excluded
from the candidate list, since they are usually expressed in
multiple types of tissues and these proteins may be from
blood and/or the analyzed tissues. Therefore, common
plasma proteins, such as fibrinogen (26), in the candidate
list were labeled as Category 3, in which proteins have
lowest priority in the candidate list for further validation
(Supplementary Table II, to be provided upon request from
the Authors).
Proteins identified and quantified by one peptide with high
probability should not be rejected, because potentially
important biological information or novel biomarkers may
be discarded before they are even provided the opportunity
of being validated (27-29). However, proteins with more than
one peptide should have higher priority than proteins with
only one peptide. Based on this criterion, proteins with one
peptide are put into Category 2, in which proteins have low
priority for further validation (Supplemental Table III, to be
provided upon request from the authors). Other proteins are
put into Category 1, in which proteins have high priority
among the entire list (Table I). 
Ranking the biomarker candidates inside each category. To
further improve success in biomarker validation, the
candidates were ranked inside each category based on
multiple factors. According to the comprehensive approach
of prioritizing and ranking (25), frequency difference, fold
change, the consistency between frequency difference and
fold change, and the number of peptides were the basic
components for ranking. These numbers were directly
available from Supplemental Table I. Besides these basic
components, subcellular location, involvement in targeted
diseases and disorders, and network connectivity from
informatics analysis were also scored and included.
In order to assign their subcellular locations, involvement
in diseases and disorders, and network connectivity, proteins
in each category were individually submitted to QIAGEN’s
Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood
City, www.qiagen.com/ingenuity) in which the Ingenuity
Pathways Knowledge Base is used. Besides subcellular
location, involvement in diseases and disorders proteins, and
network connectivity, IPA provided important information,
such as canonical pathways, upstream regulators, regulator
effects, etc. To affiliate ranking of the biomarker candidates,
only the highly related results are presented in this
publication. The network connectivity of proteins in
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Figure 1. Volcano plots of the protein changes between the follicular
adenoma and normal thyroid tissues. Only proteins highlighted in the
red square are up-regulated by at least 1.5-fold and considered potential
biomarker candidates for further prioritization and rank. Excluding
protein isoforms, 114 unique proteins were considered as biomarker
candidates.
Categories 1, 2, and 3 are presented in Figure 2 and
Supplemental Figure 1 and 2 respectively (to be provided
upon request from the Authors). The number of a protein's
connections in a network is counted and reported in Table
I, Supplemental Table I, and Supplemental Table II. The
subcellular location and the involvement in diseases and
disorders proteins of each protein are included in Table I,
Supplemental Table I, and Supplemental Table II. In this
Table, scores of 10, 7, 4, 1, and 0 were assigned for
extracellular space, plasma membrane, cytoplasm,
nucleus, and other (unknown or unassigned), respectively.
For the involvement in targeted diseases and disorders,
proteins involved in endocrine disorders were assigned 6
points, proteins related to cancer were assigned 3 points,
and proteins involved in both disorders were assigned 9
points.
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Figure 2. A merged network from three networks generated by IPA using all 47 proteins in Category 1. The gray lines show the connectivity inside
each network and the pink lines indicates new connections generated by merging the three networks into one. The connections of each protein can
be counted from the network.
Finally, a PIBAP (prioritization index of biomarker
candidates for assay of plasma/serum specimens) score was
calculated based on all numbers from the above using a
formula of FD × 10 + FC × 10 + FD × FC × 10 + NP + SS
+ SD + NC, where FD, FC, FD × FC, NP, SS,  SD , and NC
represent frequency difference, fold change, consistency
between frequency difference and fold change, number of
peptides used for protein identification, score of protein
subcellular location, score of the involvement in targeted
diseases and disorders, and connectivity in a network,
respectively. Proteins were ranked according to their PIBAP
score within each category. 
Top biomarker candidates. After categorizing and ranking,
the top five biomarker candidates in Category 1 were CD63,
DDB1, TYMP, VDAC2, and DCXR. CD63 is a cellular
membrane protein and strongly expressed in the early stages
of melanoma (30, 31). Our data showed it was 5.2-fold up-
graded in the follicular adenoma and it had the greatest fold
change among the top five candidates. DDB1 is involved in
the nucleotide excision repair pathway as a component of the
damaged DNA binding protein complex. It plays a role in
the transcriptional regulation of UV-induced genes (32).
TYMP catalyzes the reversible dephosphorylation of
thymidine, deoxyguridine, and their analogs. Its expression
is elevated in many solid tumors where it is likely involved
in mechanisms that regulate cell proliferation, apoptosis, and
angiogenesis. It has been intensively investigated to ascertain
whether TYMP is a biological marker in breast carcinoma
(33, 34). VDAC2 mediates the exchange of metabolites
through the mitochondrial membrane. Genetic and
biochemical studies have indicated that VDAC2 is anti-
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Figure 3. The upstream regulators of TGFB1 and its target proteins from Category 1. Chemical drugs or reagents highlighted in blue inhibit TGFB1,
while TGFB1 activates 10 out of the 12 proteins highlighted in red. Based on our results that the expression of proteins at the bottom is increased,
IPA predicted that the expression of TGFB1 is increased as well, but the amount of the chemicals should be decreased. If more chemicals are applied,
the expression of TGFB1 will decrease and so does the expression of the 10 proteins at the bottom. The orange lines show activation effect of six
proteins from the 10 proteins was positively confirmed by IPA. The gray lines means the other four proteins lacked literature support to predict the
activation effect of TGFB1. The yellow lines indicates our results and the literature finds in IPA are not consistent. From the IPA knowledge database,
10 chemical drugs or reagents have been found to inhibit TGFB1.
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Figure 4. The upstream regulators of NFE2L2 and its target proteins from Category 1. Based on the expression of the six proteins, IPA predicted that
NFE2L2 was activated in the follicular adenoma tissue. To inhibit the expression of NFE2L2, two chemical drugs, plicamycin and semaxinib, have
been revealed by IPA to decrease the express of NFE2L2. 
Figure 5. The upstream regulators of MYC and its target proteins from Category 1. According to literature, five out of the seven proteins are activated
by MYC. The activation effect of four of these five proteins was positively confirmed by IPA, which are shown with an orange line with an arrow at
the end. The remaining protein lacked literature support to predict the activation effect of MYC, which is shown with a gray line with an arrow at
the end. From the IPA knowledge database, six chemical drugs or reagents have been found to inhibit MYC.
apoptotic through binding and inhibition of a pro-apoptotic
multi-domain protein (35). DCXR showed a 4.3-fold
upgraded change in the follicular adenoma, the second
greatest fold change among the five proteins. It is involved in
different processes in the organism: regulation of the osmotic
state of the cellular environment, detoxification of the
cellular environment, cell to cell interaction, etc. (36).
Among the five proteins, the first four protein have been
reported to be involved in cancer. Although with no
involvement in cancer, the last one, DCXR, has extensive
functions and had a great fold changes between follicular
adenoma and normal tissues. According to the proteomics
results and the literature, they are all considered important
biomarker candidates for monitoring follicular adenoma in
clinic management in case that it develops into follicular
carcinoma. They are all highly preferred biomarker
candidates for further validation.
There are many other proteins listed in Category 1. The
other top 10 proteins have been involved in cancers, possess
great-fold change, or show good consistency between
frequency difference and fold change, making them good
candidates for further biomarker validation. Also, some
proteins in Categories 2 and 3 had good numbers in these
factor values, presenting sound reason for them to be
biomarker candidates. Although these proteins were not in
Category 1 of prioritization, the top five proteins in Category
2 and the top three proteins in Category 3 are still valuable
biomarker candidates. The category and prioritization were
only intended to validate protein candidates with the best
chance of success in a quicker and less expensive way.
Drug development target candidates for the treatment of
follicular adenoma. Using Ingenuity Pathway Analysis, a list
of upstream regulators of proteins in each category has been
discovered. For proteins in Category 1, 130 upstream
regulators show a p-value less than 0.01. Among them, eight
regulators had an activation z-score. Among the eight
regulators, four were activated proteins. Only these four
proteins, TGFB1, NFE2L2, MYC, and ANGPT2, were
considered drug development target candidates. In theory,
any chemical that is able to inhibit the expression of the four
proteins has potential to be a drug for the treatment of
follicular adenoma to prevent its worsening to follicular
carcinoma. 
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Figure 6. The upstream regulators of ANGPT2 and its target proteins from Category 1. It can be inhibited by five chemical drugs or reagents from
the IPA knowledge database and activated four proteins in Category 1, including CCT7, HSPA2, HSPA4, and ST13.
TGFB1 is a growth factor and controls proliferation,
differentiation, and other functions in many cell types (37). It
is an upstream regulator of 12 proteins in Category 1,
including ASPN, CALD1, EIF4A3, FBLN5, FLNB, HEBP1,
HEXB, HSD17B10, JUP, SHMT1, TYMP, and VDAC2
(Figure 3). According to literature, 10 out of the 12 proteins
are activated by TGFB1. The activation effect of six proteins
from the 10 proteins has been positively confirmed by IPA,
which are shown with an orange line with an arrow at the
end. The other four proteins lack literature support to predict
the activation effect of TGFB1 to them, which is shown with
a gray line with an arrow at the end. From the IPA
knowledge database, 10 chemical drugs or reagents have
been found to inhibit TGFB1. Any of them can be used in
future experiments to test their effect on TGFB1, which will
validate the discovery of this study. In the Figure, all the
orange lines indicate that the discovery of this study is
consistent with and confirmed by literature reports. The more
lines with orange color, the more confident the discovery of
this study is. Thus, Figure 3 shows TGFB1 is indeed a good
drug development target candidate.
NFE2L2 is a transcription regulator and controls the
expression of genes for several anti-oxidant enzymes, metal-
binding proteins, drug-metabolizing enzymes, drug
transporters, and molecular chaperones (38). It activates six
proteins in Category 1: CCT7, ESD, HPRT1, PSMD12,
PSMD5, and RPLP0 (Figure 4). Based on the expression of
these six proteins, IPA predicted that NFE2L2 has been
activated in the follicular adenoma tissue. According to the
literature, the activation of NRF2 may stimulate the
development of de novo cancerous tumors (39), that is
consistent with our findings. To inhibit the expression of
NFE2L2, two chemical drugs, plicamycin and semaxinib,
have been revealed by IPA to decrease the expression of
NFE2L2, leading to inhibiting proliferation and
tumorigenicity of cancer cells (40, 41). Therefore, NFE2L2
is considered as a drug target candidate.
MYC is a transcription regulator and orchestrates
transcriptional regulatory pathways underlying cell growth,
cell-cycle progression, metabolism, and survival (42). It is
an upstream regulator of seven proteins in Category 1,
including FBLN5, GOT2, H3F3A, PHB, PHB2, SHMT1,
and VDAC2 (Figure 5). IPA showed that five of the seven
proteins were activated by MYC and the activation effect of
four of the five was positively confirmed by the literature.
Also, IPA revealed six chemical drugs or reagents that were
able to inhibit MYC. MYC is overexpressed in many types
of cancers and necessary for the rapid proliferation of cancer
cells. Strategies aimed at inhibiting MYC have emerged as
effective cancer treatments (43). Small molecules targeting
MYC are promising in anticancer therapeutics (44) and
multiple therapeutic strategies have been developed to inhibit
MYC (42). These reports strongly support the candidacy of
MYC as a drug development target.
ANGPT2 is another growth factor that plays a role in
tumor angiogenesis and growth (45). It activates four
proteins in Category 1: CCT7, HSPA2, HSPA4, and ST13
(Figure 6). It can be inhibited by five chemical drugs or
reagents from the IPA knowledge database. ANGPT2
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Figure 7. Correspondence between the priority of regulators and the
rank of proteins targeted by the regulators. The Figure shows that a
regulator targeting higher-ranked proteins has a higher candidacy
priority as a drug development target, indicating that the ranking of
proteins is meaningful.
signaling has been targeted in cancer therapy (46, 47). It has
been studied as a therapeutic target in hepatocellular
carcinoma treatment (48) and  epithelial ovarian cancer (49).
The expression of ANGPT2 is normally low in quiescent
mature vessels but is strongly increased in many
inflammatory and angiogenic settings. Inhibiting ANGPT2
is to benefit the course of the disease, whether it is airway
inflammation, lung injury, or solid tumors (45). According
to our results and literature, it should be a therapeutic target
for follicular adenoma.
Although all four upstream regulators are considered as
strong candidates, their priorities in future experiments for
validation and further study should be determined in order
to improve the success. Comprehensively, considering the p-
value, activation z-score, and target molecules in dataset
provided by IPA for each regulator, the priority of TGFB1 is
much greater than the other three regulators. The priorities
of NFE2L2, MYC, and ANGPT2 are similar, but that of
NFE2L2 is slightly greater than MYC and MYC is slightly
greater than ANGPT2. To inspect the correspondence
between the priority of regulators and the rank of proteins
targeted by the regulators, a plot is generated by listing
regulators in the column and proteins in the row (Figure 7).
Figure 7 shows that a regulator targeting higher-ranked
proteins has a higher candidacy priority as a drug
development target, indicating that the ranking of proteins is
meaningful. Based on the discovery, an adjusted priority of
the regulators is TGFB1 > MYC > ANGPT2 > NFE2L2. 
Conclusion
The objective of the present study was to discover
diagnostic biomarker candidates in the clinical
management by measuring their levels in plasma, to
monitor the state and development of follicular adenoma
and find drug development targets for the treatment of
follicular adenoma, to prevent its worsening to follicular
carcinoma. As a result of the comprehensive mass
spectrometry-based analysis used in the study, we
identified biomarker and therapeutic target candidates. The
comprehensive approach to prioritize the biomarker
candidates by categorizing and ranking reveals CD63,
DDB1, TYMP, VDAC2, and DCXR as the top five
biomarker candidates. Upstream regulator analysis using
IPA discovered four therapeutic targets for follicular
adenoma. Validation of the biomarker candidates and
therapeutic targets in a follow-up study will facilitate
monitoring and treatment of follicular adenoma.
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